![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Philadelphia Eye Associates Pfizer |
---|---|
Information provided by: | Philadelphia Eye Associates |
ClinicalTrials.gov Identifier: | NCT00402493 |
The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops.
Condition | Intervention |
---|---|
Glaucoma Ocular Hypertension |
Drug: ibuprofen, latanoprost, brimonidine |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | A Prospective,Randomized,Masked,Study to Evaluate the Interaction of a Non-Steroidal Anti-Inflammatory Agent With the IOP-Lowering Effect of Brimonidine or Latanoprost. |
Estimated Enrollment: | 50 |
Study Start Date: | December 2006 |
Topical IOP-lowering therapy has the advantage of providing a drug level directly to the end organ with very little or no systemic absorption thereby reducing side effect potential. There is very little information in the ophthalmic literature regarding potential drug interactions between topical IOP-lowering medications and other medications taken orally for other medical reasons. Patients will be randomized to either latanoprost or brimonidine.
Patients in both groups will be randomized to either placebo or ibuprofen for the first 14 days and then crossed over to the other treatment for 14 days.
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Jersey | |
Philadelphia Eye Associates | |
Willingboro, New Jersey, United States, 08046 | |
United States, Pennsylvania | |
Philadelphia Eye Associates | |
Philadelphia, Pennsylvania, United States, 19148 | |
Philadelphia Eye Associates | |
Philadelphia, Pennsylvania, United States, 19134 |
Principal Investigator: | Joseph I. Markoff, Ph.D,M.D | Philadelphia Eye Associates |
Study ID Numbers: | GA6110HV |
Study First Received: | November 20, 2006 |
Last Updated: | January 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00402493 History of Changes |
Health Authority: | United States: Institutional Review Board |
Glaucoma Ocular Hypertension Xalatan Alpahgan Ibuprofen |
Non-Steroidal Anti-Inflammatory Brimonidine Latanoprost Eye Pressure Intra-Ocular Pressure |
Anti-Inflammatory Agents Neurotransmitter Agents Ibuprofen Adrenergic alpha-Agonists Adrenergic Agents Eye Diseases Cyclooxygenase Inhibitors Vascular Diseases Cardiovascular Agents Tetrahydrozoline Antihypertensive Agents |
Latanoprost Adrenergic Agonists Glaucoma Analgesics, Non-Narcotic Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Ocular Hypertension Hypertension Brimonidine |
Anti-Inflammatory Agents Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic Agonists Glaucoma Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Cardiovascular Diseases Analgesics Ibuprofen Adrenergic alpha-Agonists Eye Diseases |
Cyclooxygenase Inhibitors Vascular Diseases Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Latanoprost Pharmacologic Actions Analgesics, Non-Narcotic Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Brimonidine Ocular Hypertension Hypertension |